Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
2.040
0.00 (-0.01%)
Dec 5, 2025, 4:00 PM EST - Market closed
Company Description
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.
Mural Oncology plc
| Country | Ireland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Caroline Loew |
Contact Details
Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland | |
| Phone | 353 1 905 8020 |
| Website | muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| ISIN Number | IE000LK2BOB4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | President, Chief Executive Officer and Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Justin Levine | Head of Human Resources and Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 5, 2025 | POS AM | Post-Effective amendments for registration statement |
| Dec 5, 2025 | 25-NSE | Filing |
| Dec 5, 2025 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | 144 | Filing |
| Nov 10, 2025 | 144 | Filing |
| Nov 7, 2025 | SCHEDULE 13G/A | Filing |